Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rosalind Rei

Reporter

London, UK

Rosalind Rei has a background in science communication and business journalism. Before joining Generics Bulletin in 2022, she worked as a freelance writer and researcher covering sustainability, biotech, biomaterials, climate science, and carbon finance. She has also written and produced episodes on the history of science for the Harvard-based podcast Ministry of Ideas.

She holds a master’s in the history and philosophy of science and takes keen interests in political economy, ecology, and environment.

Latest From Rosalind Rei

Medicines For Europe And Czech Pharma Body Demand Access Reforms

Medicines For Europe and Czech association CAFF demand EU and national reforms to help drug makers ensure supply and patient access, particularly in Central and Eastern Europe.

Jubilant Seeks To Transform Business As Generics Slide

Despite a quarter-on-quarter improvement, overall sales remain in the doldrums as Jubilant mounts a multi-pronged strategy to pull through the generics decline.

Sales & Earnings Strategy

Stada And Xbrane Gain EU All-Clear For Ranibizumab Biosimilar

The European Commission has approved Stada and Xbrane’s Ximluci ranibizumab biosimilar, the third Lucentis rival to be approved in the region so far. The companies are aiming to launch in early 2023 in selected European markets.

Approvals Biosimilars

European Pharma Pushes Back Against ‘Discriminatory’ New EU Drug Pollution Proposals

Medicines for Europe, along with EFPIA and the AESGP, say that the ‘polluter pays’ principle behind proposed new European rules on wastewater treatment would saddle pharmaceutical manufacturers with costs that “jeopardize patient access.”

Europe Supply Chain

Similis Bio And Blau To Co-Develop Four Biosimilars For The Americas

JSR Life Science’s new business unit embarks on its first partnership with publicly listed Brazilian pharmaceutical.

North America South America

India And Brazil Sustain Branded Generics Success For Torrent In Q2

Torrent continues its overall growth trajectory in Q2 of its 2023 financial year, but a flagging German market slows the company’s expansion strategy. The board insists improved sales are just around the corner.

Sales & Earnings Strategy
See All
UsernamePublicRestriction

Register